Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy

Moussion, Christine; Delamarre, Lélia

doi:10.1016/j.smim.2023.101848

Cited by 2 publications

(1 citation statement)

References 260 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IFN-γ can induce tumor cell death and trigger the release of a large number of cytokines, such as CXCL9, CXCL10, and CXCL11, thereby further recruiting NK cells and macrophages to the tumor microenvironment and inducing a non-specific anti-tumor immune response [ 10 ]. In the advanced stage, the tumor cell fragments, which are left over after cell death, are phagocytosed by DCs in the tumor microenvironment, which secrete different chemokines and migrate to the draining lymph nodes [ 11 ]. Finally, the DCs present antigens to the T cells, which produce a large number of tumor antigen-specific CD4 + T cells and CD8 + T cells that specifically recognize and kill tumor cells [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Applications of Intravital Imaging in Cancer Immunotherapy

Deng,

Hao,

et al. 2024

Bioengineering

View full text Add to dashboard Cite

Currently, immunotherapy is one of the most effective treatment strategies for cancer. However, the efficacy of any specific anti-tumor immunotherapy can vary based on the dynamic characteristics of immune cells, such as their rate of migration and cell-to-cell interactions. Therefore, understanding the dynamics among cells involved in the immune response can inform the optimization and improvement of existing immunotherapy strategies. In vivo imaging technologies use optical microscopy techniques to visualize the movement and behavior of cells in vivo, including cells involved in the immune response, thereby showing great potential for application in the field of cancer immunotherapy. In this review, we briefly introduce the technical aspects required for in vivo imaging, such as fluorescent protein labeling, the construction of transgenic mice, and various window chamber models. Then, we discuss the elucidation of new phenomena and mechanisms relating to tumor immunotherapy that has been made possible by the application of in vivo imaging technology. Specifically, in vivo imaging has supported the characterization of the movement of T cells during immune checkpoint inhibitor therapy and the kinetic analysis of dendritic cell migration in tumor vaccine therapy. Finally, we provide a perspective on the challenges and future research directions for the use of in vivo imaging technology in cancer immunotherapy.

show abstract